FDA
-
-
-
-
-
-
-
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
-
-
-
-
-
-
-
Nexalin reports study shows brain stimulation device improved chronic insomnia
-
-
-
-
-
-
-
Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market
-
-
-
-
-
-
-
FDA accepts Nexalin Q-submission for Alzheimer's treatment device
-
-
-
-
-
-
-
Nexalin Technology (NXL) CEO Provides Letter to Shareholders
-
-
-
-
-
323,944 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

